Apmonia Therapeutics
PrivateLast Round
Series A
Feb 3, 2026
Total Funding Raised
$17.4M
Company Overview
Apmonia Therapeutics is a biotechnology company that develops peptide-based immunotherapy strategies for the treatment of solid tumors by targeting the tumor microenvironment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Apmonia Therapeutics Comparables
Compare Apmonia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PEP-Therapy | 85% | |
| Sapience Therapeutics | 81% | |
| Vigeo Therapeutics | 81% |
Apmonia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 3, 2026 | ||||
| Grant | Jul 16, 2024 | ||||
| Grant | Apr 23, 2024 | ||||
| VC Round | Feb 10, 2022 |
Key People
Founding team and executive leadership
Apmonia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| France 2030 | Grant |
| European Innovation Council Fund | Grant |
| Angels Santé | Series A, VC Round |
| Finovam Gestion | Series A, VC Round |
| Capital Grand Est | Series A, VC Round |
| Business Angels Marne Ardennes | Seed |
| Capital Cell | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Monthly visitors increased 83% MoM.
- Feb 21, 2026
Grew 27% QoQ from 15 to 19 employees.
Apmonia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Apmonia Therapeutics's valuation, stock price, and market status.
Is Apmonia Therapeutics a public or private company?
Apmonia Therapeutics is a private company.
What is the current stock price of Apmonia Therapeutics?
Apmonia Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Apmonia Therapeutics worth (valuation)?
Valuation information for Apmonia Therapeutics is not publicly available.
Can I buy Apmonia Therapeutics stock?
Apmonia Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Apmonia Therapeutics's last funding round?
Apmonia Therapeutics's most recent funding round was Series A on February 3, 2026.
Who are the main investors in Apmonia Therapeutics?
Key investors in Apmonia Therapeutics include France 2030, European Innovation Council, Angels Santé, Finovam Gestion, Capital Grand Est.
Will Apmonia Therapeutics IPO soon?
No public IPO plans have been announced for Apmonia Therapeutics.
How can I track Apmonia Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Apmonia Therapeutics's secondary market activity and sign up for updates.